This model builds upon previous AGAS models that involve simulated metastatic disease via tail vein injection of tumor cells,30 combining the experimental surgical stress from those models with an established immune-competent model of MYCN-amplified HR-NB, which has been utilized to investigate combined immunotherapy in HR-NB.25 The gene discussed is MYCN; the disease is neoplasm.